SG Americas Securities LLC Buys 5,172 Shares of Hologic, Inc. (NASDAQ:HOLX)

SG Americas Securities LLC boosted its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 116.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,609 shares of the medical equipment provider's stock after buying an additional 5,172 shares during the quarter. SG Americas Securities LLC's holdings in Hologic were worth $594,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Venturi Wealth Management LLC boosted its stake in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co boosted its stake in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares in the last quarter. Finally, Raiffeisen Bank International AG purchased a new stake in Hologic in the fourth quarter worth approximately $49,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.88% of the stock is owned by corporate insiders.

Hologic Trading Up 0.8%

Shares of Hologic stock traded up $0.51 during midday trading on Friday, reaching $64.48. 5,564,249 shares of the company's stock traded hands, compared to its average volume of 2,349,728. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The company has a market cap of $14.37 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 2.36 and a beta of 0.55. The stock has a 50 day moving average of $59.29 and a 200-day moving average of $64.28. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.03 earnings per share. As a group, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several recent research reports. Morgan Stanley lowered their price objective on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Evercore ISI lowered their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Royal Bank Of Canada lowered their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Citigroup lowered their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Hologic has an average rating of "Hold" and a consensus price target of $77.42.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.